Skip to main
QURE

uniQure (QURE) Stock Forecast & Price Target

uniQure (QURE) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 45%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

uniQure NV is positioned favorably due to its robust pipeline of gene therapies, particularly with the encouraging data from its AMT-130 program for Huntington's disease, which reflects a strong efficacy and biomarker package recognized by the scientific community. Additionally, the positive interim data from the AMT-260 trial for mesial temporal lobe epilepsy and the collaboration with Bristol Myers Squibb for cardiovascular diseases further enhances its growth prospects. The absence of new regulatory concerns regarding manufacturing or safety, combined with a favorable risk-benefit profile for its therapies, reinforces a positive outlook for the company's future financial performance.

Bears say

The analysis indicates a negative outlook on uniQure's stock primarily due to significant delays in the submission timeline for its lead product, AMT-130, which have prompted the company to withdraw previous guidance for a BLA submission that was slated for early 2026. Furthermore, the company faces substantial financial risks as a clinical-stage entity with no revenue-generating products and a history of ongoing losses since its inception, which continues to undermine investor confidence. Increased market competition for similar indications presents an additional challenge that could adversely affect uniQure’s market penetration and pricing strategies, compounding the company’s difficulties in the current environment.

uniQure (QURE) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 45% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About uniQure (QURE) Forecast

Analysts have given uniQure (QURE) a Buy based on their latest research and market trends.

According to 11 analysts, uniQure (QURE) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

uniQure (QURE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.